Qi Liang

Ms. Qi Liang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 October 2022 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
XJXingyu Jiang
Xingyu Jiang
QLQi Liang
Qi Liang
HXHuanhuan Xu
Huanhuan Xu
SGShouyong Gu
Shouyong Gu
LLLingxiang Liu
Lingxiang Liu
Aims. This paper aims to investigate the relationship of waist circumference (WC) with digestive tract cancer morbidity and mortality. Methods. Based on the data from a nationally representative US population survey, we summarized the prevalence of digestive tract cancer and all-cause mortality of cancer patients across WC quartiles. Adjusted logistic regression and restricted spline curve were used to analyze WC and the prevalence of digestive tract cancer. Moreover, Cox regression and the Kaplan-Meier curve were applied to investigate the association of WC with all-cause mortality. We also attempted to make a model to predict cancer happening. Results. This paper included a total of 34,041 participants, with digestive tract cancer observed in 265 (0.7) individuals. WC was positively associated with digestive tract cancer morbidity after full adjustment of covariates (OR: 1.72 and 95 CI: 1.41-2.10). Also, individuals in the highest WC group had a higher risk of digestive tract cancer (Q4, OR: 2.71 and 95 CI: 1.48-5.00). Moreover, no significant association was observed in upper digestive cancer, and WC was associated with a longer survival time once diagnosed (hazard ratio (HR): 0.50 and 95 CI: 0.28-0.92). Finally, the model we made proved to be effective. Conclusion. High WC is a risk factor for digestive tract cancer with or without adjusting for body mass index, especially those located in the lower digestive tract. However, once digestive tract cancer has been diagnosed, patients with higher WC showed better survival outcomes. Moreover, machine learning methods can be used to predict digestive tract cancer risk in the future.

28 November 2025 in Cancer Science
Verified
Journal Article
Open access
YJYuQin Jiang
YuQin Jiang
QLQi Liang
Qi Liang
YZYuting Zhu
Yuting Zhu
XLXiao Liang
Xiao Liang
RHRuohan Huang
Ruohan Huang
RGRenhua Guo
Renhua Guo
FLAURA2 has demonstrated that third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) plus chemotherapy brought a significant survival benefit over EGFR‐TKI monotherapy. This suggests that EGFR‐TKIs combined with chemotherapy may be a viable therapeutic strategy. Our study aimed to evaluate the efficacy, safety, and progression pattern of third‐generation EGFR‐TKIs combined with chemotherapy in advanced EGFR ‐mutant ( EGFR m) non‐small cell lung cancer (NSCLC) in the real world. This study designed as an observational, retrospective, single‐center, real‐world project enrolled 382 NSCLC individuals receiving third‐generation EGFR‐TKIs combined with platinum‐based chemotherapy as first‐line therapy. The primary end point was progression‐free survival (PFS), and secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). From July 2016 to May 2024, 382 patients were retrospectively included for the analysis. Of these patients, 120, 165, and 97 patients received osimertinib, aumolertinib, and furmonertinib plus chemotherapy as first‐line therapy, respectively. Overall, the median follow‐up duration was 34.6 months (95% CI: 32.2–35.6), the median PFS was 30.9 months (95% CI: 27.5–39.3), and the median OS was 53.9 months (95% CI: 46.2–NR). Overall, the ORR was 76.4% and the DCR was 98.2%. One hundred thirty‐seven (35.9%) individuals experienced Grade 3 or higher AEs. Different third‐generation EGFR‐TKI groups show no statistically significant difference in PFS (HR = 0.75; 95% CI: 0.51–1.10; p = 0.25) after inverse probability of treatment weighting (IPTW), nor in AEs or severe AEs ( p = 0.852; p = 0.502). First‐line third‐generation EGFR‐TKI combined with pemetrexed‐based chemotherapy demonstrated a favorable ORR and PFS benefit in advanced EGFR m NSCLC.

13 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YWYuemin Wu
Yuemin Wu
Runwei GuanRunwei Guan
Runwei Guan
XLXiao Liang
Xiao Liang
WZWei Zhang
Wei Zhang
YJYuqin Jiang
Yuqin Jiang
RGRenhua Guo
Renhua Guo
The aim of the present study was to predict the response of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitors (ICIs) by leveraging computed tomography (CT) images using deep learning techniques. Retrospectively, 624 sequential CT images were gathered from 156 patients at Jiangsu Province Hospital, along with their clinical data. The dataset was subsequently partitioned into three groups: training (n=547), validation (n=64), and test (n=64). Moreover, an external validation cohort included 37 CT images from patients at Nanjing Pukou Peoples' Hospital, accompanied by comprehensive clinical data. An advanced Video Vision Transformer (ViViT) model incorporating global self-attention was utilized to analyse patients treated with ICIs and predict their response. The ViViT model's efficacy was evaluated using a confusion matrix and a receiver operating characteristic curve (ROC). Notably, the ViViT model demonstrated predictive prowess for ICIs response, yielding respective areas under the receiver operating characteristic curve (AUC) of 0.74 (95% CI: 0.69-0.78), 0.74 (95% CI: 0.61-0.86), 0.76 (95% CI: 0.62-0.88), and 0.69 (95% CI: 0.5-0.87) in the training, validation, test, and external validation cohorts. The present study illustrates how a deep learning model can provide a non-invasive means to predict clinical outcomes in NSCLC patients undergoing ICIs, potentially transforming personalized treatment approaches for individuals with NSCLC.